NVO, BMRN And ILMN, 3 Health Care Stocks Pushing The Sector Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 28 points (-0.2%) at 17,094 as of Thursday, Aug. 28, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,204 issues advancing vs. 1,745 declining with 194 unchanged.

The Health Care sector currently sits down 0.3% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the sector include Grifols ( GRFS), down 1.2%, Sanofi ( SNY), down 1.1%, Express Scripts ( ESRX), down 1.0%, Baxter International ( BAX), down 0.7% and Alexion Pharmaceuticals ( ALXN), down 0.6%. Top gainers within the sector include Centene ( CNC), up 2.8%, Aetna ( AET), up 0.8%, Bristol-Myers Squibb Company ( BMY), up 0.7% and Humana ( HUM), up 0.5%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Novo Nordisk A/S ( NVO) is one of the companies pushing the Health Care sector lower today. As of noon trading, Novo Nordisk A/S is down $0.40 (-0.9%) to $45.65 on average volume. Thus far, 467,382 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 894,400 shares. The stock has ranged in price between $45.59-$45.76 after having opened the day at $45.73 as compared to the previous trading day's close of $46.05.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $126.1 billion and is part of the drugs industry. Shares are up 24.6% year-to-date as of the close of trading on Wednesday. Currently there are 2 analysts that rate Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Novo Nordisk A/S Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Biomarin Pharmaceutical ( BMRN) is down $0.91 (-1.3%) to $69.89 on light volume. Thus far, 363,093 shares of Biomarin Pharmaceutical exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $69.56-$71.10 after having opened the day at $69.91 as compared to the previous trading day's close of $70.80.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Biomarin Pharmaceutical has a market cap of $10.5 billion and is part of the drugs industry. Shares are up 0.6% year-to-date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Biomarin Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Biomarin Pharmaceutical Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Illumina ( ILMN) is down $1.08 (-0.6%) to $178.86 on average volume. Thus far, 549,113 shares of Illumina exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $178.03-$180.15 after having opened the day at $179.82 as compared to the previous trading day's close of $179.94.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $25.0 billion and is part of the drugs industry. Shares are up 62.7% year-to-date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Illumina a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, expanding profit margins, good cash flow from operations and compelling growth in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Illumina Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing